Daxiang Biotech joined the 14th Tumor Models Summit Boston, held July 29–30, 2026, alongside researchers and industry leaders working to advance more predictive and translationally relevant models for oncology drug development.

Daxiang Biotech has been recognized as the “Top Organoids-on-Chips Model Services in Asia 2026” by Life Sciences Review, highlighting the company’s innovation and contributions to advancing organoid-on-chip technologies for biomedical research, drug discovery, and preclinical development.

Daxiang Biotech joined global leaders in Microphysiological Systems (MPS) research and innovation at MPS World Summit 2026, where the company showcased its integrated Organoids-on-Chips platform and engaged with researchers, industry partners, and innovators from around the world.

Daxiang Biotech utilized the IBAC O2 chip to construct a tumor organoid immune co-culture model. This model effectively recreated the immune microenvironment of human tumors and evaluated the efficacy of QLF3108.

Humanized and highly advanced organoids on chips models have emerged as a crucial technology platform for evaluating cell therapy drugs and conducting translational medicine research. Data of organoids on chips facilitate clinical approval of CAR-T drugs for solid tumors.

On April 12, 2022, Daxiang Biotech and Nikon signed a strategic cooperation agreement .